Prognostication is tenous in early scleroderma, especially in those with diffuse cutaneous systemic sclerosis (dcSSc). dcSSc has associated with substantial morbidity and disease-specific mortality. Analysis of an early SSc registry shows that anti-RNA polymerase III autoantibodies in early SSc were associated a higher risk of worse phenotypes and clinical outcomes.
A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.
Dr. John Cush RheumNow
3 days 12 hours ago
Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved ≥1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ https://t.co/EdAqXfsjW0
Dr. John Cush RheumNow
3 days 14 hours ago
Single center, DBRPCT of tofacitinib 11 mg/d vs PBO in 100 knee OA pts (KL Gr 1-2); At wk 12 there was NO significant differences betw groups in VAS Pain, or other outcomes-WOMAC, Oxford Knee Score, EQ-5D-5L, analgesic use https://t.co/VDtgY7hTm4 https://t.co/PveouQbI8r
Are there any data that GLP-1 RA drugs can be effective if a person has a normal BMI?
Dr. John Cush RheumNow
4 days 5 hours ago
Phenotypic cluster analysis of 134 CPPD pts from COLCHICORT & CHRONIC-CPPD European cohorts ID 4 Grps: 1) C1 monoarticular recurrent flares, older, W, ^CRP; 2) C2 monoarticular w persistent arthritis; 3) C3 polyarthritis lower CRP; 4) C4 polyarticular (spine/shoulder( & recurrent https://t.co/ghMCmDLCki
Dr. John Cush RheumNow
4 days 7 hours ago
True or False: The TriNetX retrospective study found that JAK inhibitors significantly increased VTE risk in rheumatoid arthritis patients undergoing hip or knee replacement compared to TNF inhibitors.
Check your knowledge in the latest RheumIQ quiz at https://t.co/LHFv1P6XZe.
The Endocrine Society has published a scientific statement reframing obesity as a heterogeneous, chronically dysregulated fat-mass disorder, the biology of which is being tested effectively by GLP-1/GIP receptor agonists. Is this precision-medicine? We await long-term safety data, while assessing the outcomes in rheumatic and musculoskeletal disorders.
Dr. John Cush RheumNow
4 days 9 hours ago
CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). https://t.co/MPgLpr7LPP
Dr. John Cush RheumNow
4 days 9 hours ago
17 Sept EMA CHMP recommended marketing authorisation for secukinumab (Cosentyx) in the treatment of polymyalgia rheumatica. BUT- not yet EMA approved in the EU. https://t.co/ZGUSbw06vX https://t.co/EqRwpT8Sxo
Dr. John Cush RheumNow
4 days 10 hours ago
Join us for Tuesday Nite Rheumatology on September 22 for:
🔴 Obesity Treatment & Safety
Experts will tackle:
• GLP-1/GIP therapies
• Lifestyle & bariatric interventions
• Treatment selection & safety
• Cost & compounding concerns
• Sarcopenia & bone health
• The future https://t.co/YNEsGofRR9
Dr. John Cush RheumNow
4 days 12 hours ago
Observational study of 63,215 neuropsychiatric (NP) pts showed semaglutide signif lowered NP events over 2yrs (vs metformin, SGLT2 inhibitors, DPP-4 inhib);unrelaed to wt loss. Less substance, mood anxiety, CNS atrophies, neuromuscular, eating/sleep & personality/impulse-control https://t.co/tbuvLRK3QE
Dr. John Cush RheumNow
4 days 14 hours ago
EBR Journal Club: Obexelimab in IgG4-Related Disease (INDIGO)
The EBR Journal Club Companion applies my adapted JAMA approach to critical appraisal to an important rheumatology RCT. Each review covers four domains: Does this apply to my patients? What is the risk of bias? How https://t.co/rH7BY21FvF
